Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Historical Holders from Q4 2018 to Q3 2025

Symbol: CLDX on Nasdaq
Type / Class: Equity / Common Stock, par value $.001
Shares outstanding: 65,833,370
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 70,727,286
Holdings value: $1,829,751,733
% of all portfolios: 0.003%
Number of holders: 177
Number of buys: 87
Number of sells: -83
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
WELLINGTON MANAGEMENT GROUP LLP	11.1%	+40%	$191,302,079	+$55,941,805	7,394,746	+41.3%	Wellington Management Group LLP	31 Oct 2025
Kynam Capital Management, LP	9.79%	+27%	$136,045,000	+$30,051,147	6,500,000	+28.4%	Kynam Capital Management, LP	31 Mar 2025
FMR LLC	7.3%		$101,670,991		4,857,668		FMR LLC	31 Dec 2024
BlackRock, Inc.	7.3%	-12.5%	$100,867,802	-$13,842,621	4,819,293	-12.1%	BlackRock, Inc.	31 Mar 2025
Point72 Asset Management, L.P.	6.7%		$90,854,558		4,464,400		Point72 Asset Management, L.P.	02 Jul 2025
Bellevue Group AG	5.4%		$93,589,097		3,617,669		Bellevue Group AG	18 Aug 2025
Commodore Capital LP	4.6%	-8%	$78,343,026	-$8,321,474	3,028,335	-9.6%	Commodore Capital LP	30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/	3.6%	-36%	$61,640,475	-$30,382,633	2,382,701	-33%	T. Rowe Price Associates, Inc.	30 Sep 2025
EVENTIDE ASSET MANAGEMENT, LLC	2%		$30,459,938		1,356,186		Eventide Asset Management, LLC	30 Jun 2025

Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	70,727,286	$1,829,751,733	-$41,022,171	$5,650,008	$2,450,443	$25.87	177
2025 Q2	72,686,329	$1,479,214,886	-$18,971,957	$4,511,595	$1,855,278	$20.35	178
2025 Q1	73,628,376	$1,336,550,222	-$25,518,368	$5,343,360	$1,671,615	$18.15	170
2024 Q4	73,686,767	$1,861,792,917	-$10,935,353	$16,657,984	$21,023,110	$25.27	172
2024 Q3	71,809,989	$2,440,639,326	+$62,002,971	$32,280,303	$52,959,667	$33.99	174
2024 Q2	69,594,154	$2,575,716,559	+$1,332,092	$5,903,095	$2,908,986	$37.01	181
2024 Q1	69,311,318	$2,908,781,828	+$362,625,073	$9,653,100	$6,866,292	$41.97	196
2023 Q4	60,989,057	$2,418,831,729	+$410,573,840	$16,157,518	$18,025,470	$39.66	162
2023 Q3	50,572,705	$1,391,763,899	+$5,531,719	$13,347,200	$15,557,056	$27.52	140
2023 Q2	50,188,683	$1,702,972,802	+$19,493,416	$3,699,063	$3,597,580	$33.93	148
2023 Q1	49,503,692	$1,779,547,358	+$24,122,749	$7,595,378	$15,604,500	$35.98	158
2022 Q4	48,677,430	$2,169,609,749	-$9,316,822	$8,842,467	$23,595,452	$44.57	163
2022 Q3	49,338,461	$1,386,923,833	+$32,333,656	$5,160,760	$14,094,647	$28.11	146
2022 Q2	48,218,738	$1,300,004,065	-$45,672,202	$49,658,336	$95,975,448	$26.96	146
2022 Q1	49,602,527	$1,689,417,077	+$106,143,717	$34,685,960	$54,623,612	$34.06	157
2021 Q4	46,338,765	$1,790,195,856	+$97,400,922	$33,954,600	$76,784,400	$38.64	170
2021 Q3	43,227,306	$2,333,703,184	+$430,296,249	$57,670,760	$84,047,000	$53.99	156
2021 Q2	35,559,554	$1,189,106,240	+$60,325,552	$37,072,000	$32,572,000	$33.44	127
2021 Q1	34,503,199	$709,497,850	-$40,255,166	$13,601,200	$20,638,000	$20.6	109
2020 Q4	36,816,222	$645,045,236	+$72,177,637	$7,159,000	$10,386,000	$17.52	120
2020 Q3	32,156,087	$476,873,776	+$67,764,471	$3,043,000	$7,399,000	$14.83	82
2020 Q2	27,786,246	$361,216,517	+$310,785,532	$2,747,000	$10,331,000	$13	63
2020 Q1	3,949,694	$6,557,892	+$7,227	$22,000	$67,000	$1.66	32
2019 Q4	3,904,189	$8,706,543	+$447,617	$29,000	$67,000	$2.23	34
2019 Q3	3,708,146	$7,895,004	+$465,004	$65,000	$108,000	$2.13	40
2019 Q2	3,466,005	$9,286,115	+$2,108,302	$102,000	$180,000	$2.68	39
2019 Q1	2,603,854	$12,809,043	+$12,313,782		$346,000	$4.92	39
2018 Q4	100,357	$20,000	+$20,000			$0.1993	1